Transcriptomics

Dataset Information

0

IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming


ABSTRACT: To understand the role of polyploid giant cancer cells (PGCCs) in drug resistance and disease relapse, we examined the mRNA expression profile of PGCCs in ovarian cancer cells. An acute activation of IL-6 dominated senescence associated secretory phenotype lasted 2-3 weeks and declined during the termination phase of polyploidy. IL-6 activates embryonic stemness during the initiation of PGCCs and can reprogram normal fibroblasts into cancer-associated fibroblasts (CAFs) via increased collagen synthesis, activation of VEGF expression, and enrichment of CAFs and the GPR77+/CD10+ fibroblast subpopulation. Blocking the IL-6 feedback loop with tocilizumab or apigenin prevented PGCC formation, attenuated embryonic stemness and the CAF phenotype, and inhibited tumor growth in a patient-derived xenograft high-grade serous ovarian carcinoma model. Thus, IL-6 derived by PGCCs is capable of reprogramming both cancer and stromal cells and contributes to the evolution and remodeling of cancer. Targeting IL-6 in PGCCs may represent a novel approach to combating drug resistance

ORGANISM(S): Homo sapiens

PROVIDER: GSE178745 | GEO | 2021/06/24

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2023-08-08 | GSE229119 | GEO
2023-12-01 | GSE248717 | GEO
2018-02-14 | GSE106519 | GEO
2016-03-21 | GSE77318 | GEO
2014-09-11 | E-GEOD-40595 | biostudies-arrayexpress
| EGAD00001010322 | EGA
2024-10-30 | GSE280564 | GEO
2022-11-09 | GSE213453 | GEO
2013-12-31 | GSE40266 | GEO
2023-05-01 | GSE229529 | GEO